세계의 B형 간염 백신 시장(2024년)

The global Hepatitis B Vaccines market was valued at US$ 1269 million in 2023 and is anticipated to reach US$ 1985 million by 2030, witnessing a CAGR of 6.45% during the forecast period 2024-2030.

North American market for Hepatitis B Vaccines is estimated to increase from $ 568 million in 2023 to reach $ 964 million by 2030, at a CAGR of 7.48% during the forecast period of 2024 through 2030.

Asia-Pacific market for Hepatitis B Vaccines is estimated to increase from $ 397.5 million in 2023 to reach $ 554.68 million by 2030, at a CAGR of 4.92% during the forecast period of 2024 through 2030.

The major global manufacturers of Hepatitis B Vaccines include GSK, NCPC, Merck, Bio Kangtai, Dynavax, AIM Vaccine, KM Biologics, LG Life Sciences, Serum Institute, etc. In 2023, the world's top five vendors accounted for approximately 79.66% of the revenue.

This report aims to provide a comprehensive presentation of the global market for Hepatitis B Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Vaccines.

The Hepatitis B Vaccines market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis B Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hepatitis B Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

• GSK
• NCPC
• Merck
• Bio Kangtai
• Dynavax
• AIM Vaccine
• KM Biologics
• LG Life Sciences
• Serum Institute

Segment by Type

• Yeast Derived
• CHO Derived

Segment by Application

• Children
• Adult

Consumption by Region

• North America
• U.S.
• Canada
• Mexico
• Asia-Pacific
• China
• Japan
• South Korea
• India
• Southeast Asia
• Europe
• Germany
• France
• U.K.
• Italy
• Benelux
• Rest of Europe
• South America
• Brazil
• Other
• Middle East & Africa
• Middle East
• Africa

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Hepatitis B Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Hepatitis B Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

Table of Contents

1 Hepatitis B Vaccines Market Overview

• 1.1 Product Definition
• 1.2 Hepatitis B Vaccines by Type
  • 1.2.1 Global Hepatitis B Vaccines Market Value Comparison by Type (2024-2030)
  • 1.2.2 Yeast Derived
  • 1.2.3 CHO Derived
• 1.3 Hepatitis B Vaccines by Application
  • 1.3.1 Global Hepatitis B Vaccines Market Value by Application (2024-2030)
  • 1.3.2 Children
  • 1.3.3 Adult
• 1.4 Global Hepatitis B Vaccines Market Size Estimates and Forecasts
  • 1.4.1 Global Hepatitis B Vaccines Revenue 2019-2030
  • 1.4.2 Global Hepatitis B Vaccines Sales 2019-2030
  • 1.4.3 Global Hepatitis B Vaccines Market Average Price (2019-2030)
• 1.5 Assumptions and Limitations

2 Hepatitis B Vaccines Market Competition by Manufacturers

• 2.1 Global Hepatitis B Vaccines Sales Market Share by Manufacturers (2019-2024)
• 2.2 Global Hepatitis B Vaccines Revenue Market Share by Manufacturers (2019-2024)
• 2.3 Global Hepatitis B Vaccines Average Price by Manufacturers (2019-2024)
• 2.4 Global Key Players of Hepatitis B Vaccines, Industry Ranking, 2022 VS 2023 VS 2024
• 2.5 Global Key Manufacturers of Hepatitis B Vaccines, Manufacturing Sites & Headquarters
• 2.6 Global Key Manufacturers of Hepatitis B Vaccines, Product Type & Application
• 2.7 Global Key Manufacturers of Hepatitis B Vaccines, Date of Enter into This Industry
• 2.8 Global Hepatitis B Vaccines Market Competitive Situation and Trends
  • 2.8.1 Global Hepatitis B Vaccines Market Concentration Rate
  • 2.8.2 The Global 5 and 9 Largest Hepatitis B Vaccines Players Market Share by Revenue
  • 2.8.3 Global Hepatitis B Vaccines Market by Company Type (Tier 1, Tier 2, and Tier 3)
• 2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Hepatitis B Vaccines Market Scenario by Region

• 3.1 Global Hepatitis B Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
• 3.2 Global Hepatitis B Vaccines Sales by Region: 2019-2030
  • 3.2.1 Global Hepatitis B Vaccines Sales by Region: 2019-2024
  • 3.2.2 Global Hepatitis B Vaccines Sales by Region: 2025-2030
• 3.3 Global Hepatitis B Vaccines Revenue by Region: 2019-2030
  • 3.3.1 Global Hepatitis B Vaccines Revenue by Region: 2019-2024
  • 3.3.2 Global Hepatitis B Vaccines Revenue by Region: 2025-2030
• 3.4 North America Hepatitis B Vaccines Market Facts & Figures by Country
  • 3.4.1 North America Hepatitis B Vaccines Market Size by Country: 2019 VS 2023 VS 2030
  • 3.4.2 North America Hepatitis B Vaccines Sales by Country (2019-2030)
  • 3.4.3 North America Hepatitis B Vaccines Revenue by Country (2019-2030)
  • 3.4.4 U.S.
  • 3.4.5 Canada
  • 3.4.6 Mexico
• 3.5 Europe Hepatitis B Vaccines Market Facts & Figures by Country
  • 3.5.1 Europe Hepatitis B Vaccines Market Size by Country: 2019 VS 2023 VS 2030
  • 3.5.2 Europe Hepatitis B Vaccines Sales by Country (2019-2030)
  • 3.5.3 Europe Hepatitis B Vaccines Revenue by Country (2019-2030)
  • 3.5.4 Germany
  • 3.5.5 France
  • 3.5.6 U.K.
  • 3.5.7 Italy
  • 3.5.8 Benelux
• 3.6 Asia Pacific Hepatitis B Vaccines Market Facts & Figures by Region
  • 3.6.1 Asia Pacific Hepatitis B Vaccines Market Size by Region: 2019 VS 2023 VS 2030
  • 3.6.2 Asia Pacific Hepatitis B Vaccines Sales by Region (2019-2030)
  • 3.6.3 Asia Pacific Hepatitis B Vaccines Revenue by Region (2019-2030)
  • 3.6.4 China
  • 3.6.5 Japan
  • 3.6.6 South Korea
  • 3.6.7 India
  • 3.6.8 Southeast Asia
• 3.7 South America Hepatitis B Vaccines Market Facts & Figures by Country
  • 3.7.1 South America Hepatitis B Vaccines Market Size by Country: 2019 VS 2023 VS 2030
  • 3.7.2 South America Hepatitis B Vaccines Sales by Country (2019-2030)
  • 3.7.3 South America Hepatitis B Vaccines Revenue by Country
  • 3.7.4 Brazil
• 3.8 Middle East and Africa Hepatitis B Vaccines Market Facts & Figures by Country
  • 3.8.1 Middle East and Africa Hepatitis B Vaccines Market Size by Country: 2019 VS 2023 VS 2030
  • 3.8.2 Middle East and Africa Hepatitis B Vaccines Sales by Country (2019-2030)
  • 3.8.3 Middle East and Africa Hepatitis B Vaccines Revenue by Country
  • 3.8.4 Middle East
  • 3.8.5 Africa

4 Segment by Type

• 4.1 Global Hepatitis B Vaccines Sales by Type (2019-2030)
  • 4.1.1 Global Hepatitis B Vaccines Sales by Type (2019-2024)
  • 4.1.2 Global Hepatitis B Vaccines Sales by Type (2025-2030)
  • 4.1.3 Global Hepatitis B Vaccines Sales Market Share by Type (2019-2030)
• 4.2 Global Hepatitis B Vaccines Revenue by Type (2019-2030)
  • 4.2.1 Global Hepatitis B Vaccines Revenue by Type (2019-2024)
  • 4.2.2 Global Hepatitis B Vaccines Revenue by Type (2025-2030)
  • 4.2.3 Global Hepatitis B Vaccines Revenue Market Share by Type (2019-2030)
• 4.3 Global Hepatitis B Vaccines Price by Type (2019-2030)

5 Segment by Application

• 5.1 Global Hepatitis B Vaccines Sales by Application (2019-2030)
  • 5.1.1 Global Hepatitis B Vaccines Sales by Application (2019-2024)
  • 5.1.2 Global Hepatitis B Vaccines Sales by Application (2025-2030)
  • 5.1.3 Global Hepatitis B Vaccines Sales Market Share by Application (2019-2030)
• 5.2 Global Hepatitis B Vaccines Revenue by Application (2019-2030)
  • 5.2.1 Global Hepatitis B Vaccines Revenue by Application (2019-2024)
  • 5.2.2 Global Hepatitis B Vaccines Revenue by Application (2025-2030)
  • 5.2.3 Global Hepatitis B Vaccines Revenue Market Share by Application (2019-2030)
• 5.3 Global Hepatitis B Vaccines Price by Application (2019-2030)

6 Key Companies Profiled

• 6.1 GSK
  • 6.1.1 GSK Company Information
  • 6.1.2 GSK Description and Business Overview
  • 6.1.3 GSK Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.1.4 GSK Hepatitis B Vaccines Product Portfolio
• 6.2 NCPC
  • 6.2.1 NCPC Company Information
  • 6.2.2 NCPC Description and Business Overview
  • 6.2.3 NCPC Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.2.4 NCPC Hepatitis B Vaccines Product Portfolio
• 6.3 Merck
  • 6.3.1 Merck Company Information
  • 6.3.2 Merck Description and Business Overview
  • 6.3.3 Merck Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.3.4 Merck Hepatitis B Vaccines Product Portfolio
• 6.4 Bio Kangtai
  • 6.4.1 Bio Kangtai Company Information
  • 6.4.2 Bio Kangtai Description and Business Overview
  • 6.4.3 Bio Kangtai Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.4.4 Bio Kangtai Hepatitis B Vaccines Product Portfolio
• 6.5 Dynavax
  • 6.5.1 Dynavax Company Information
  • 6.5.2 Dynavax Description and Business Overview
  • 6.5.3 Dynavax Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.5.4 Dynavax Hepatitis B Vaccines Product Portfolio
  • 6.5.5 Dynavax Recent Developments/Updates
• 6.6 AIM Vaccine
  • 6.6.1 AIM Vaccine Company Information
  • 6.6.2 AIM Vaccine Description and Business Overview
  • 6.6.3 AIM Vaccine Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.6.4 AIM Vaccine Hepatitis B Vaccines Product Portfolio
• 6.7 KM Biologics
  • 6.7.1 KM Biologics Company Information
  • 6.7.2 KM Biologics Description and Business Overview
  • 6.7.3 KM Biologics Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.7.4 KM Biologics Hepatitis B Vaccines Product Portfolio
• 6.8 LG Life Sciences
  • 6.8.1 LG Life Sciences Company Information
  • 6.8.2 LG Life Sciences Description and Business Overview
  • 6.8.3 LG Life Sciences Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.8.4 LG Life Sciences Hepatitis B Vaccines Product Portfolio
  • 6.8.5 LG Life Sciences Recent Developments/Updates
• 6.9 Serum Institute
  • 6.9.1 Serum Institute Company Information
  • 6.9.2 Serum Institute Description and Business Overview
  • 6.9.3 Serum Institute Hepatitis B Vaccines Sales, Revenue and Gross Margin (2019-2024)
  • 6.9.4 Serum Institute Hepatitis B Vaccines Product Portfolio

7 Industry Chain and Sales Channels Analysis

• 7.1 Hepatitis B Vaccines Industry Chain Analysis
• 7.2 Hepatitis B Vaccines Key Raw Materials
  • 7.2.1 Key Raw Materials
  • 7.2.2 Raw Materials Key Suppliers
• 7.3 Hepatitis B Vaccines Production Mode & Process
• 7.4 Hepatitis B Vaccines Sales and Marketing
  • 7.4.1 Hepatitis B Vaccines Sales Channels
  • 7.4.2 Hepatitis B Vaccines Distributors
• 7.5 Hepatitis B Vaccines Customers

8 Hepatitis B Vaccines Market Dynamics

• 8.1 Hepatitis B Vaccines Industry Trends
• 8.2 Hepatitis B Vaccines Market Drivers
• 8.3 Hepatitis B Vaccines Market Challenges
• 8.4 Hepatitis B Vaccines Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

• 10.1 Methodology/Research Approach
  • 10.1.1 Research Programs/Design
  • 10.1.2 Market Size Estimation
  • 10.1.3 Market Breakdown and Data Triangulation
• 10.2 Data Source
  • 10.2.1 Secondary Sources
  • 10.2.2 Primary Sources
• 10.3 Author List
• 10.4 Disclaimer